OSUCCC – James Cancer Diagnostic Center speeds up diagnosis, treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new center at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute gives patients direct, expedited access to diagnostic testing for cancer.

The center’s goal is to provide immediate community-wide patient access to cancer providers for anyone with a suspected cancer, especially in communities where access to healthcare is limited and has become more challenging during the COVID-19 pandemic.

The James Cancer Diagnostic Center offers a platform for expert evaluation and access to the appropriate diagnostic testing so that a cancer diagnosis can be made in a timely and precise manner, in a low-risk environment. Center visits can be virtual or in-person based on the patient’s preference.

Launched on June 15, the Cancer Diagnostic Center is open daily and staffed by a team of advanced practice professionals and nurses who have expertise in oncology. The team is overseen by physicians with oncology experience and expertise.

The center is available for both self- or physician-referral. Center staff first identify and prioritize patient needs and concerns and then coordinate appropriate testing and evaluation on behalf of the patient at facilities within The James and the Ohio State Wexner Medical Center. Follow-up care is also coordinated with a specialized, multidisciplinary team at The James if a cancer diagnosis is made.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login